Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 3/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4926507 | 0.90 | THRA (0.40) | THRATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL4926964 | 0.90 | ALDH1A1 (0.39) | THRATHRBTACR1KMT2AMEN1 | |
| SCHEMBL4934553 | 0.90 | GRM4 (0.38) | THRATHRBCRHR1ALDH1A1L3MBTL1 | |
| SCHEMBL5718067 | 0.88 | THRA (0.37) | THRATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL4931728 | 0.86 | THRA (0.42) | THRATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL4934426 | 0.84 | THRA (0.45) | THRATHRB | |
| SCHEMBL4933128 | 0.84 | TRPA1 (0.41) | THRATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL4934307 | 0.84 | CYP1A2 (0.37) | THRATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL5108656 | 0.84 | ALDH1A1 (0.46) | THRATHRBKMT2AMEN1ALDH1A1 | |
| SCHEMBL5110746 | 0.84 | RORC (0.40) | THRATHRBKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | KARO BIO AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1732533-A1 | THYROID RECEPTOR AGONISTS | KARO BIO AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092317-A1 | THYROID RECEPTOR AGONISTS | KARO BIO AB (SE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | TSHR, TRHR, THRA | THRA 3/4885THRB 4/4885TACR1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.